Delivery Order SPE2DR25D3021-SPE2DR26FS8LR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for SPIKEVAX 2025-26 (6M-11Y) syringes at a ceiling value of $1,261.08 under a firm fixed-price contract. The delivery order, which became effective on December 2, 2025, with an ultimate completion date of December 23, 2025, is for pediatric COVID-19 vaccine doses in single 0.25 mL syringes. This award represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $2,605.16 firm fixed price delivery order to AmerisourceBergen Drug Corp for SPIKEVAX 2025-26 (6M-11Y) syringes at 0.25ml on October 29, 2025, with completion scheduled for November 20, 2025. This is a non-set-aside competitive award for pediatric COVID-19 vaccine delivery to support federal immunization programs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor...
- The Defense Logistics Agency awarded a $6,305.30 delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for Spikevax 2025-26 pediatric vaccines (6 months to 11 years) in 0.25 mL syringes, with completion targeted for December 22, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The product will be performed at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $4,413.71 delivery order to AmerisourceBergen Drug Corp on December 6, 2025, for Spikevax 2025-26 vaccine doses (0.25mL syringes for ages 6-11 years) with completion by December 29, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,195.01 to AmerisourceBergen Drug Corp for SPIKEVAX 2025-26 (6M-11Y) Syringe 0.25ML, a pediatric COVID-19 vaccine formulation. This firm fixed price delivery order, awarded on October 29, 2025, with an ultimate completion date of November 20, 2025, represents a non-set-aside competitive award. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for SPIKEVAX 2025-26 (6M-11Y) syringes in 0.25ML doses, valued at $3,152.65 with a firm fixed price structure. The award, issued on November 24, 2025, is a non-set-aside competitive contract with an ultimate completion date of December 16, 2025. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $6,088.75 to AmerisourceBergen Drug Corp for SPIKEVAX 2025-26 (6M-11Y) syringes at 0.25mL on September 24, 2025, with completion scheduled for September 25, 2025. This competitively awarded, firm fixed-price delivery order was placed under no set-aside and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The product supplied—a pediatric COVID-19 vaccine formulation for children ages 6 months to 11...
- The Defense Logistics Agency awarded a delivery order valued at $3,999.60 to AmerisourceBergen Drug Corp for the supply of SPIKEVAX 2025-26 (6M-11Y) syringes at 0.25mL. This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 9, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a pediatric vaccine product supporting federal medical supply requirements under the Defense Health Agency's...
- The Defense Logistics Agency awarded a delivery order valued at $17,353.95 to AmerisourceBergen Drug Corp for Spikevax 2025-26 vaccine doses (6 months to 11 years, 0.25 mL syringes) on November 7, 2025, with completion required by December 2, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $3,152.65 to AmerisourceBergen Drug Corp for Spikevax 2025-26 vaccine doses (6M-11Y) in 0.25ML syringes, with performance in Conshohocken, Pennsylvania and completion by December 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999...
- SPE2DR25D3021Indefinite Delivery Contract
- SPE2DR25D3021-SPE2DR26FS8LRDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,152.65 to AmerisourceBergen Drug Corp for Spikevax 2025-26 (6M-11Y) syringes at 0.25mL, with a completion date of December 24, 2025. This competitively awarded, firm fixed-price delivery order represents a pediatric COVID-19 vaccine supply for the federal medical supply chain. The award is issued without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal medical procurement across the Department of Defense healthcare systems, supplying a comprehensive portfolio of vaccines, medications, and medical supplies to support military personnel and veterans. The company's extensive contract portfolio with DLA demonstrates its capability to fulfill diverse federal pharmaceutical requirements through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 12/2/25 |